首页> 外文期刊>生物医学研究杂志(英文版) >An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer
【24h】

An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer

机译:CA19-9和CEA水平对胰腺癌的诊断价值评价

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:The use of a combination of tumor markers may be an important tool in the early diagnosis of pancreatic cancer, which is the key to improving prognosis. The study aim was to investigate the diagnostic value of carbohydrate antigen 19-9(CA 19-9) and carcinoembryonic antigen(CEA) levels in patients with pancreatic cancer. Methods:An immunoradiometric assay was used to homochronously measure the serum CA19-9 and CEA levels in 78 pancreatic cancer cases and 64 healthy examinees in hospital. The normal reference values were CA19-9(0-39 U/ml) and CEA(0-3.4 ng/ml). Results: Mean serum CA 19-9 and CEA levels in patients with pancreatic cancer(406.55±60.18 U/ml, 12.43±1.25 ng/ml) were significantly higher(P<0.01) than those in healthy examinees(16.54 ± 1.95 U/ml, 2.37 ± 0.17 ng/ml).The sensitivity of the combined detection of CA19-9 and CEA (92.31%) was significantly higher(P < 0.05) than that of either marker alone (79.49%, 71.79%, respectively). In addition, the sensitivity to diagnose pancreatic cancer by detecting the serum CA19-9 and CEA levels was higher(P < 0.05) in stage Ⅱ B +Ⅲ + Ⅳ(87.04%, 79.23%) than stage Ⅰ + Ⅱ A(62.50%, 54.17%). Conclusion: The combined detection of CA19-9 and CEA could overcome the deficiency of using single marker detection by improving the sensitivity to diagnose pancreatic cancer. At the same time, CA19-9 and CEA detection could be used to assess mesenteric artery invasion and the metastasis of lymphatics and distant organs in pancreatic cancer.
机译:目的:结合多种肿瘤标志物可能是胰腺癌早期诊断的重要手段,这是改善预后的关键。本研究旨在探讨碳水化合物抗原19-9(CA 19-9)和癌胚抗原(CEA)水平对胰腺癌的诊断价值。方法:采用免疫放射分析法同时测定78例胰腺癌患者和64例健康体检者的血清CA19-9和CEA水平。正常参考值为CA19-9(0-39 U / ml)和CEA(0-3.4 ng / ml)。结果:胰腺癌患者平均血清CA 19-9和CEA水平(406.55±60.18 U / ml,12.43±1.25 ng / ml)显着高于健康受试者(16.54±1.95 U / ml)(P <0.01)。 ml,2.37±0.17 ng /ml。CA19-9和CEA的联合检测灵敏度(92.31%)显着高于任何一个单独的标记物(分别为79.49%,71.79%)(P <0.05)。另外,通过检测血清CA19-9和CEA水平诊断胰腺癌的敏感性在ⅡB +Ⅲ+Ⅳ期(87.04%,79.23%)比Ⅰ+ⅡA期(62.50%)更高(P <0.05)。 ,54.17%)。结论:CA19-9和CEA的联合检测可通过提高诊断胰腺癌的敏感性,克服单一标记物检测的不足。同时,CA19-9和CEA检测可用于评估胰腺癌肠系膜动脉的侵袭以及淋巴管和远处器官的转移。

著录项

  • 来源
    《生物医学研究杂志(英文版)》 |2009年第3期|199-202|共4页
  • 作者单位

    Department of Hepatobiliary Surgery, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an 710061, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 内科学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号